Abstract
Loss of heterozygosity (LOH) at human chromosome 18q, which includes the gene Deleted in Colorectal Cancer (DCC), has been linked to colorectal and many other human cancers. DCC encodes the receptor for the axon guidance molecule Netrin (Net) and functions during neural development in a variety of organisms. However, since its discovery in the 1990s, the status of DCC as a tumor suppressor has been debated, primarily due to a lack of support for this hypothesis in animal models. A recent study from our laboratory capitalized on the genetic tractability of Drosophila melanogaster to demonstrate that this gene functions as an invasive tumor suppressor, thereby providing the first direct link between DCC loss and metastatic phenotypes in an animal model for cancer. Two subsequent studies from other laboratories have demonstrated that DCC suppresses tumor progression and metastasis in murine colorectal and mammary tumor models. Combined, these findings have prompted the rebirth of DCC as a tumor suppressor and highlighted the need for continued analysis of DCC function in animal models for human cancer.
Keywords: Apoptosis, axon guidance, cancer, DCC, Drosophila melanogaster, metastasis, netrin, tumor suppressor, LOH, metastatic phenotype.
Current Drug Targets
Title:Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Volume: 13 Issue: 11
Author(s): Molly Duman-Scheel
Affiliation:
Keywords: Apoptosis, axon guidance, cancer, DCC, Drosophila melanogaster, metastasis, netrin, tumor suppressor, LOH, metastatic phenotype.
Abstract: Loss of heterozygosity (LOH) at human chromosome 18q, which includes the gene Deleted in Colorectal Cancer (DCC), has been linked to colorectal and many other human cancers. DCC encodes the receptor for the axon guidance molecule Netrin (Net) and functions during neural development in a variety of organisms. However, since its discovery in the 1990s, the status of DCC as a tumor suppressor has been debated, primarily due to a lack of support for this hypothesis in animal models. A recent study from our laboratory capitalized on the genetic tractability of Drosophila melanogaster to demonstrate that this gene functions as an invasive tumor suppressor, thereby providing the first direct link between DCC loss and metastatic phenotypes in an animal model for cancer. Two subsequent studies from other laboratories have demonstrated that DCC suppresses tumor progression and metastasis in murine colorectal and mammary tumor models. Combined, these findings have prompted the rebirth of DCC as a tumor suppressor and highlighted the need for continued analysis of DCC function in animal models for human cancer.
Export Options
About this article
Cite this article as:
Duman-Scheel Molly, Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor, Current Drug Targets 2012; 13 (11) . https://dx.doi.org/10.2174/138945012803530215
DOI https://dx.doi.org/10.2174/138945012803530215 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ErbB Antagonists Patenting: “Playing Chess with Cancer”
Recent Patents on Biotechnology Free Fatty Acid Receptors as New Potential Targets in Colorectal Cancer
Current Drug Targets Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
Protein & Peptide Letters Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2
Current Neurovascular Research The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Rational Drug Design of Antineoplastic Agents Using 3D-QSAR, Cheminformatic, and Virtual Screening Approaches
Current Medicinal Chemistry Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Metabolism of Dietary Flavonoids in Liver Microsomes
Current Drug Metabolism Patent Selections
Recent Patents on DNA & Gene Sequences Phytogenic Polyphenols as Glycogen Phosphorylase Inhibitors: The Potential of Triterpenes and Flavonoids for Glycaemic Control in Type 2 Diabetes
Current Medicinal Chemistry Regulation of the Urokinase Receptor (uPAR) by LDL Receptor-related Protein-1 (LRP1)
Current Pharmaceutical Design Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents
Current Pharmaceutical Biotechnology Involvement of CD24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy
Current Cancer Drug Targets The Use of Methylphenidate for Physical and Psychological Symptoms in Cancer Patients: A Review
Current Drug Targets Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Recent Progress in Predicting Posttranslational Modification Sites in Proteins
Current Topics in Medicinal Chemistry Triple Treatment with Octreotide, Galanin and Serotonin is a Promising Therapy for Colorectal Cancer
Current Pharmaceutical Design